Plx Pharma Inc Quick Ratio (PLXP) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Plx Pharma Inc   (NASDAQ: PLXP)

Plx Pharma Inc 's Quick Ratio

PLXP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Plx Pharma Inc 's Cash & cash equivalent, this led to improvement in Plx Pharma Inc 's Quick Ratio to 4.97, Quick Ratio remained below Plx Pharma Inc average.

Within Major Pharmaceutical Preparations industry 304 other companies have achieved higher Quick Ratio than Plx Pharma Inc in third quarter 2022. While Quick Ratio total ranking has improved so far during the Q3 2022 to 1003, from total ranking in the second quarter 2022 at 1011.

Explain Quick Ratio?
How much Cash & cash equivalents PLXP´s has?
What are PLXP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PLXP Quick Ratio (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3
Y / Y Current Liabilities Change -20.8 % 227.2 % 1004.12 % 354.55 % 112.26 %
Y / Y Cash & cash equivalent Change -68.71 % -55.43 % -37.81 % 209.11 % 808.54 %
Quick Ratio MRQ 4.97 4.28 4.09 6.48 12.57
PLXP's Total Ranking # 1003 # 1011 # 1040 # 751 # 452
Seq. Current Liabilities Change -37.64 % -35.03 % 19.78 % 63.21 % 157.62 %
Seq. Cash & cash equivalent Change -27.7 % -31.94 % -24.34 % -15.94 % 2.97 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 305
Healthcare Sector # 499
Overall Market # 1003


Quick Ratio Statistics
High Average Low
72.62 19.53 1.85
(Mar 31 2021)   (Mar 31 2020)




Financial Statements
Plx Pharma Inc 's Current Liabilities $ 5 Millions Visit PLXP's Balance sheet
Plx Pharma Inc 's Cash & cash equivalent $ 26 Millions Visit PLXP's Balance sheet
Source of PLXP's Sales Visit PLXP's Sales by Geography


Cumulative Plx Pharma Inc 's Quick Ratio

PLXP's Quick Ratio for the trailling 12 Months

PLXP Quick Ratio

 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 193.57 % 319.75 % 189.3 % 38.6 % -28.68 %
Y / Y Cash & cash equivalent TTM Growth -31.95 % 22.46 % 120.26 % 485.33 % 490.81 %
Quick Ratio TTM 4.95 6.25 8.71 15.08 21.34
Total Ranking TTM # 4278 # 691 # 4050 # 178 # 3545
Seq. Current Liabilities TTM Growth -3.55 % 17.73 % 55.61 % 66.16 % 37.9 %
Seq. Cash & cash equivalent TTM Growth -23.62 % -15.61 % -10.09 % 17.41 % 37.46 %

Quick ratio ranking by company, industry and sector >> Back to PLXP Financial Strength Comparisons >> Go to Compare PLXP Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in PLXP's Current Liabilities to $5.20 millions, cumulative Quick Ratio to 4.95 below the PLXP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 575 other companies have achieved higher Quick Ratio than Plx Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 691 to 4278.

Explain Quick Ratio?
How much Cash & cash equivalents PLXP´s has?
What are PLXP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 576
Healthcare Sector # 1145
Within the Market # 4278


trailing twelve months Quick Ratio Statistics
High Average Low
17.48 7.51 2.24
(Sep 30 2021)   (Sep 30 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Rani Therapeutics Holdings Inc   13.66 $ 98.171  Millions$ 7.186  Millions
Lumos Pharma Inc   13.44 $ 73.666  Millions$ 5.483  Millions
Annexon Inc   13.33 $ 269.519  Millions$ 20.220  Millions
Larimar Therapeutics Inc   13.24 $ 124.699  Millions$ 9.420  Millions
Liquidia Corporation  13.18 $ 98.320  Millions$ 7.460  Millions
Xenetic Biosciences Inc   13.18 $ 13.848  Millions$ 1.051  Millions
Psyence Biomedical ltd   13.05 $ 0.605  Millions$ 0.046  Millions
Aclaris Therapeutics Inc   13.04 $ 248.062  Millions$ 19.023  Millions
Iveric Bio Inc   13.04 $ 320.535  Millions$ 24.588  Millions
Erasca Inc   12.86 $ 355.928  Millions$ 27.679  Millions
Arcutis Biotherapeutics Inc   12.86 $ 476.963  Millions$ 37.102  Millions
Kronos Bio Inc   12.85 $ 258.255  Millions$ 20.105  Millions
Verrica Pharmaceuticals Inc   12.82 $ 39.454  Millions$ 3.078  Millions
Lyell Immunopharma Inc   12.65 $ 648.132  Millions$ 51.217  Millions
Pepgen Inc   12.62 $ 195.783  Millions$ 15.519  Millions
Calcimedica Inc   12.61 $ 43.627  Millions$ 3.460  Millions
Histogen Inc   12.41 $ 14.552  Millions$ 1.173  Millions
Onkure Therapeutics Inc   12.28 $ 116.080  Millions$ 9.450  Millions
Cogent Biosciences Inc   12.28 $ 289.094  Millions$ 23.551  Millions
Neurogene Inc   12.18 $ 107.870  Millions$ 8.858  Millions
Chemomab Therapeutics Ltd   12.15 $ 46.466  Millions$ 3.824  Millions
Cymabay Therapeutics Inc   12.07 $ 153.415  Millions$ 12.711  Millions
Acrivon Therapeutics Inc   12.02 $ 76.823  Millions$ 6.391  Millions
Rallybio Corporation  11.90 $ 132.420  Millions$ 11.130  Millions
Kalvista Pharmaceuticals Inc   11.88 $ 122.273  Millions$ 10.294  Millions
Milestone Pharmaceuticals Inc   11.84 $ 77.233  Millions$ 6.522  Millions
Capricor Therapeutics inc   11.84 $ 46.614  Millions$ 3.937  Millions
Lisata Therapeutics Inc   11.82 $ 75.530  Millions$ 6.391  Millions
Ideaya Biosciences Inc   11.80 $ 386.244  Millions$ 32.727  Millions
Allakos Inc   11.79 $ 325.320  Millions$ 27.588  Millions

Date modified: 2026-09-08T15:10:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.